Evaluation of osteoporosis treatments in patients undergoing TKA.

Evaluation of osteoporosis treatments in patients undergoing TKA. - The influence of the drug for the treatment of osteoporosis on the proximal tibia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015290

Enrollment

Registered

2014-09-30

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the knee Osteoporosis

Interventions

Resedronate 17.5mg/week Teriparatide 56.5ug/week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Osteoporosis patients with high risk of bone fracture who is scheduled to have either BP or Teriparatide treatment* prior to TKA. * BP (Resedronate 17.5/week) or Teriparatide 56.5ug/week is administered 3 months prior to TKA.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Bone density at lumbar spine, bone metabolism markers (PINP, ucOC, TRACP-5b), KL score, KSS, CT on knee, and density and structure of excised samples.	—

Countries

Japan

Contacts

Public ContactKenichiro Takashiba

Medical Co. LTA Fukuoka Mirai hospital Bone and joint center

k-takashiba@fukuoka-mirai.jp0926623535

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026